Transcript segment

Baric Transcribed Interview (Redacted), p.119 · baric_ti:utt:01027

Date: 2026-04-10 09:00 (day precision)
Type: transcript segment · interview
recipient: Ralph S. Baric, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
speaker: Christina Salazar

It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model."

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

2026-04-10 09:00 Ralph S. Baric open

Whatever the shipping cost are. DC.Scheduling@LexitasLegal.com
2026-04-10 09:00 Christina Salazar open

Okay. And how much are shipping costs?
2026-04-10 09:00 Ralph S. Baric open

You know, I haven't shipped anything. I have somebody else I have to do it. We have a person who's trained as a shipper, and they take care of it.
2026-04-10 09:00 Christina Salazar open

Okay. I want to go back to the DARPA question on PREEMPT. I'll show you this email, and I don't have another copy of it right now. But it is dated March 7, 2019. It's from Vineet Menarchery, and you have a couple of other folks on here from Autonomous Therapeutics. [Exhibit No. 3 shown.]
2026-04-10 09:00 Christina Salazar

It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model."
2026-04-10 09:00 Ralph S. Baric open

Okay.
2026-04-10 09:00 Christina Salazar open

Do you recognize this?
2026-04-10 09:00 Ralph S. Baric open

Within the contest of Vineet, yes.
2026-04-10 09:00 Christina Salazar open

Did you end up doing work with -- DC.Scheduling@LexitasLegal.com

Full conversation →